Sorafenib-Induced Liver Failure: A Case Report and Review of the Literature
In patients with hepatocellular carcinoma characterized by vascular invasion and/or extrahepatic disease, Sorafenib is considered treatment of choice. Although mild liver test abnormalities were reported in less than 1% of the patients in the two large randomized, controlled phase III trials, four...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2011-01-01
|
| Series: | Case Reports in Hepatology |
| Online Access: | http://dx.doi.org/10.1155/2011/941395 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832559207299153920 |
|---|---|
| author | Anneleen Van Hootegem Chris Verslype Werner Van Steenbergen |
| author_facet | Anneleen Van Hootegem Chris Verslype Werner Van Steenbergen |
| author_sort | Anneleen Van Hootegem |
| collection | DOAJ |
| description | In patients with hepatocellular carcinoma characterized by vascular invasion and/or extrahepatic disease, Sorafenib is considered treatment of choice. Although mild liver test abnormalities were reported in less than 1% of the patients in the two large randomized, controlled phase III trials, four cases of severe acute Sorafenib-induced hepatitis have been described. One of these four cases died from liver failure. In this paper, a patient with HCC with lung metastases developed high fever and a severe hepatitis that rapidly evolved into liver coma and death, two weeks after the initiation of Sorafenib. Biochemical parameters pointed to a hepatocellular type of injury. Clinical and biochemical presentations were compatible with a drug-induced hypersensitivity syndrome such as it has mainly been described for aromatic anticonvulsants, sulphonamides, and allopurinol. We hypothesize that an underlying cytochrome P450 dysfunction with the presence of reactive drug metabolites might lead to this potentially fatal Sorafenib-induced severe liver dysfunction. |
| format | Article |
| id | doaj-art-530a5497a75e4bcbba5ecc3d55da4ca3 |
| institution | Kabale University |
| issn | 2090-6587 2090-6595 |
| language | English |
| publishDate | 2011-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Hepatology |
| spelling | doaj-art-530a5497a75e4bcbba5ecc3d55da4ca32025-02-03T01:30:38ZengWileyCase Reports in Hepatology2090-65872090-65952011-01-01201110.1155/2011/941395941395Sorafenib-Induced Liver Failure: A Case Report and Review of the LiteratureAnneleen Van Hootegem0Chris Verslype1Werner Van Steenbergen2Liver Unit, Department of Pathophysiology, University Hospital Gasthuisberg, Catholic University of Leuven, 3000 Leuven, BelgiumLiver Unit, Department of Pathophysiology, University Hospital Gasthuisberg, Catholic University of Leuven, 3000 Leuven, BelgiumLiver Unit, Department of Pathophysiology, University Hospital Gasthuisberg, Catholic University of Leuven, 3000 Leuven, BelgiumIn patients with hepatocellular carcinoma characterized by vascular invasion and/or extrahepatic disease, Sorafenib is considered treatment of choice. Although mild liver test abnormalities were reported in less than 1% of the patients in the two large randomized, controlled phase III trials, four cases of severe acute Sorafenib-induced hepatitis have been described. One of these four cases died from liver failure. In this paper, a patient with HCC with lung metastases developed high fever and a severe hepatitis that rapidly evolved into liver coma and death, two weeks after the initiation of Sorafenib. Biochemical parameters pointed to a hepatocellular type of injury. Clinical and biochemical presentations were compatible with a drug-induced hypersensitivity syndrome such as it has mainly been described for aromatic anticonvulsants, sulphonamides, and allopurinol. We hypothesize that an underlying cytochrome P450 dysfunction with the presence of reactive drug metabolites might lead to this potentially fatal Sorafenib-induced severe liver dysfunction.http://dx.doi.org/10.1155/2011/941395 |
| spellingShingle | Anneleen Van Hootegem Chris Verslype Werner Van Steenbergen Sorafenib-Induced Liver Failure: A Case Report and Review of the Literature Case Reports in Hepatology |
| title | Sorafenib-Induced Liver Failure: A Case Report and Review of the Literature |
| title_full | Sorafenib-Induced Liver Failure: A Case Report and Review of the Literature |
| title_fullStr | Sorafenib-Induced Liver Failure: A Case Report and Review of the Literature |
| title_full_unstemmed | Sorafenib-Induced Liver Failure: A Case Report and Review of the Literature |
| title_short | Sorafenib-Induced Liver Failure: A Case Report and Review of the Literature |
| title_sort | sorafenib induced liver failure a case report and review of the literature |
| url | http://dx.doi.org/10.1155/2011/941395 |
| work_keys_str_mv | AT anneleenvanhootegem sorafenibinducedliverfailureacasereportandreviewoftheliterature AT chrisverslype sorafenibinducedliverfailureacasereportandreviewoftheliterature AT wernervansteenbergen sorafenibinducedliverfailureacasereportandreviewoftheliterature |